[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haiyan Wang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100586987","pacemaker-related-tricuspid-regurgitation-progression-and-long-term-outcomes-100586987",false,"NCT06922526","Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes","Predictors of Tricuspid Regurgitation Progression and Adverse Outcomes in Different Pacing Modes","Inclusion Criteria:\n\n1. Adult patients\n2. Patients with an implantable electronic heart device (CIEDs)\n3. The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025\n\nExclusion Criteria:\n\n1. Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation\n2. Patients with severe valvular heart disease, congenital heart disease, or arrhythmias\n3. Patients with single-chamber pacemakers or poor images","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.\n\nThis study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.",[24,25],"Tricuspid Regurgitation","Pacemaker","RECRUITING","2025-04-26",{"date":29,"type":30},"2025-04-30","ACTUAL",{"date":32,"type":20},"2025-04",{"date":34,"type":20},"2026-05",{"name":36,"class":37},"Haiyan Wang","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100531153","myocardial-stiffness-evaluation-in-patients-with-heart-failure-with-preserved-ejection-fraction-100531153","NCT06196086","Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction","Evaluation of Myocardial Stiffness in Patients With Heart Failure With Preserved Ejection Fraction by Intrinsic Wave Velocity Propagation","Inclusion Criteria:\n\nMeet the diagnostic criteria for HFpEF in the 2022 AHA\u002FACC\u002FHFSA Guidelines for Heart Failure Management:\n\n* Present with signs and symptoms of heart failure;\n* LVEF≥50%;\n* There is at least one additional criterion: Increased BNP (BNP≥35pg\u002Fml, NT-pro BNP\\>125pg\u002Fml) and resting echocardiography measured E\u002Fe' ≥ 15; Stress echocardiography determined E\u002Fe' ≥ 15; Cardiac catheterization at rest, PCWP ≥ 15 mmHg or LVEDP ≥ 16 mmHg; The PCWP at peak exercise was ≥ 25 mmHg.\n\nExclusion Criteria:\n\n* Acute coronary syndrome, acute heart failure or coronary revascularization in three months;\n* HFimpEF, cardiomyopathy, severe valvular heart disease, arrhythmia;\n* Thyroid dysfunction, pulmonary hypertension, past or current pulmonary embolism, severe chronic obstructive pulmonary disease, malignancy\u002Frenal failure (less than 30) ml\u002Fmin);\n* Poor echocardiogram image quality.",true,"80 Years",{"count":49,"type":20},438,"The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP). The main questions it aims to answer are:\n\n* Whether myocardial stiffness assessed by IVP in patients with HFpEF Increased.\n* Whether IVP is related to the cardiac structure and function in patients with HFpEF.\n* What are the risk factors that may be associated with heart failure rehospitalization in patients with HFpEF?\n* Whether increased myocardial stiffness is a risk factor for heart failure rehospitalization.\n\nParticipants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, and software post-processing analysis to obtained two-dimensional strain parameters and IVP, as well as general clinical data and laboratory test results. Clinical followed up was performed through electronic medical records or telephone interviews until patient rehospitalization for heart failure or discharge for one year.",[52],"Heart Failure With Preserved Ejection Fraction","2024-01-08",{"date":55,"type":30},"2024-01-09",{"date":57,"type":30},"2023-12-20",{"date":59,"type":20},"2027-12-20",{"name":36,"class":37},""]